Dose Insider / Glossary

GLP-1 glossary100 terms, defined from their sources

Updated November 20, 2026

Plain definitions of the drugs, trials and medical words that come up with GLP-1 medicines. Each entry starts with a two-sentence answer, then gives the numbers from the FDA label or the trial behind it, with the sources.

100 termsdrugs, trials and medical words, each defined from its primary sources
Terms by subject100 entries, each with its sourcesDrugs30Trials26Science19Safety8Dosing5Compounding3Terms by subject100 entries, each with its sourcesDrugs30Trials26Science19Safety8Dosing5Compounding3

Every definition links to the analyses that use it.

On this page

5

A

B

C

D

E

F

G

H

I

K

L

M

N

O

P

Q

R

S

SarcopeniaSarcopenia is a muscle disease, or muscle failure, rooted in harmful changes in muscle that build up over a lifetime. SaxendaSaxenda is a brand of liraglutide, a once-daily injection made by Novo Nordisk for weight management. SCALE DiabetesSCALE Diabetes is the trial of liraglutide 3.0 mg, the dose later sold as Saxenda, for weight in people with type 2 diabetes. SCALE MaintenanceSCALE Maintenance tested whether liraglutide 3.0 mg, the dose sold as Saxenda, helps keep off weight lost by dieting. SELECTSELECT is the trial that showed semaglutide lowers heart risk in people with excess weight who do not have diabetes. SemaglutideSemaglutide is a lab-made version of the gut hormone GLP-1, changed so that it lasts about a week in the body. SNACSNAC, short for salcaprozate sodium, is an absorption enhancer: an inactive ingredient that helps another drug get into the body. STEP 1STEP 1 is the main trial behind the approval of Wegovy for weight management. STEP 2STEP 2 is the trial of semaglutide for weight in people with type 2 diabetes. STEP 4STEP 4 is the trial that tested what happens when semaglutide is stopped. STEP TEENSSTEP TEENS is the trial that led to the approval of Wegovy for adolescents. STEP-HFpEFSTEP-HFpEF is the trial of semaglutide in people with obesity and heart failure with preserved ejection fraction, a form of heart failure in which the Subcutaneous injectionA subcutaneous injection, often written SQ or sub-Q, is a shot given into the fatty tissue just under the skin, rather than into a muscle or a vein.1 SUMMITSUMMIT is the trial of tirzepatide in people with obesity and heart failure with preserved ejection fraction, the form of heart failure in which the h SURMOUNT-1SURMOUNT-1 is the main trial behind the approval of Zepbound for weight management. SURMOUNT-2SURMOUNT-2 is the trial of tirzepatide for weight in people with type 2 diabetes. SURMOUNT-3SURMOUNT-3 tested whether tirzepatide adds to weight already lost through diet and exercise. SURMOUNT-5SURMOUNT-5 is the trial that compared tirzepatide, the drug in Zepbound, directly with semaglutide, the drug in Wegovy, for weight management. SURMOUNT-OSASURMOUNT-OSA is a pair of trials that tested tirzepatide for obstructive sleep apnea in adults with obesity. SURPASS-2SURPASS-2 is the trial that put tirzepatide head to head with semaglutide in type 2 diabetes. SurvodutideSurvodutide is an experimental weekly injection from Boehringer Ingelheim that activates two receptors, those for glucagon and for GLP-1, which makes SUSTAIN 6SUSTAIN 6 is the cardiovascular trial of semaglutide in people with type 2 diabetes, the trial behind Ozempic's heart indication. SwitchingSwitching means moving from one GLP-1 medicine to another, or from one form of the same medicine to another, such as from a weekly injection to a dail SYNERGY-NASHSYNERGY-NASH is a phase 2 trial of tirzepatide in metabolic dysfunction-associated steatohepatitis, or MASH, the inflammatory form of fatty liver dise

T

V

W

Z

Log every dose in mg with the vial it came from, so there is a record if something goes wrong.

Open Dose Insider